Determinants of high cost in multiple sclerosis patients: a claims and chart review study.

about

Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015

P2860

Q33638157-1B09F0AF-6940-4B8E-A84A-0D4E3AE21EEE Q36240512-96159E7B-BBC3-41F7-A525-F375B3D5BE44

P2860

Determinants of high cost in multiple sclerosis patients: a claims and chart review study.

Item

http://www.wikidata.org/entity/Q38840408

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Determinants of high cost in m ...... claims and chart review study.

@en

type

Item

label

Determinants of high cost in m ...... claims and chart review study.

@en

prefLabel

Determinants of high cost in m ...... claims and chart review study.

@en

P1476

Determinants of high cost in m ...... claims and chart review study.

@en

P2093

Bernard B Tulsi

http://www.w3.org/2001/XMLSchema#string

Debra F Eisenberg Lawrence

http://www.w3.org/2001/XMLSchema#string

Howard S Friedman

http://www.w3.org/2001/XMLSchema#string

Prakash Navaratnam

http://www.w3.org/2001/XMLSchema#string

Rahul Sasane

http://www.w3.org/2001/XMLSchema#string

Timothy Vollmer

http://www.w3.org/2001/XMLSchema#string

Xuehua Ke

http://www.w3.org/2001/XMLSchema#string

P2860

Cost of managing an episode of relapse in multiple sclerosis in the United States

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Oral treatment for multiple sclerosis

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Primary progressive multiple sclerosis: progress and challenges.

Multiple sclerosis.

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.

P304

1589-1597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03007995.2016.1192529

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27207562

http://www.w3.org/2001/XMLSchema#string

Determinants of high cost in multiple sclerosis patients: a claims and chart review study.

about

P2860

P2860

Determinants of high cost in multiple sclerosis patients: a claims and chart review study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698